Teva to buy Allergan generic drug business for $40.5 billion, drops Mylan bid

Teva Pharmaceutical Industries has agreed to buy Allergan Plc's generic drugs business for $40.5 billion in a cash and stock deal that will turn the Israeli company into one of the world's largest pharmaceutical firms.

Read Full Article

Teva nears deal for Allergan's generic drugs unit: source

Teva Pharmaceutical Industries Ltd (TEVA.TA) is in advanced talks to buy Allergan Plc's (AGN.N) generic drug business following a thus far unsuccessful effort to acquire peer Mylan NV (MYL.O), according to a person familiar with the matter.

Read Full Article

Teva plans to raise Mylan bid by as much as $2 billion: Bloomberg

Teva Pharmaceutical Industries Ltd (TEVA.TA) is preparing to raise its bid for rival drugmaker Mylan NV (MYL.O) by as much as $2 billion, to $43 billion, Bloomberg reported on Monday, citing people familiar with the matter.

Read Full Article

Mylan says Teva offer too low; criticizes stock, growth prospects

Mylan NV (MYL.O) rejected Teva Pharmaceutical Industries Ltd's (TEVA.TA) $40 billion takeover offer on Monday, saying in a scathing letter that it grossly undervalued the company and that Mylan has no interest in payment in what it termed "high-risk" Teva stock.

Read Full Article

U.S. companies may not be fleeing due to high tax rate, Reuters analysis shows

When a series of big U.S. companies last year moved to reincorporate abroad in inversion deals, some Republican lawmakers and tax policy critics blamed the high U.S. corporate tax rate. Lowering it, they said, would keep companies from fleeing the country.

Read Full Article

Boehringer subsidiary hires Bank of America to explore sale of injectable drugs business

Ben Venue Laboratories, a subsidiary of German Boehringer Ingelheim in the US, has engaged Bank of American Merill Lynch to advise it on a proposed sale of its sterile injectable drugs business.

Read Full Article

Mylan, two Indian firms race to buy Bafna Pharma

US-based generic drug manufacturer Mylan and two Indian pharmaceutical firms are in talks to buy Chennai-based Bafna Pharmaceuticals for an undisclosed amount, according to two sources familiar with the transaction.

Read Full Article

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics